Navigation Links
New therapeutic target for prostate cancer identified
Date:7/17/2012

New Rochelle, NY, July 16, 2012A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer. Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. This promising new strategy for improving the effectiveness of anti-androgenic and other hormonal therapies is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.. The article is available free online at the BioResearch Open Access website.

Prostate cancer is the most common non-skin cancer affecting men and the second most common cause of cancer death among men. In the article "miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2," Xiaoping Yang, Lynne Bernis, Lih-Jen Su, Dexiang Gao, and Thomas Flaig, University of Colorado Denver (Aurora) and University of Minnesota (Duluth), looked for targets of microRNA-125b that might shed light on its role in regulating prostate cancer and found that it directly inhibits NCOR2, which acts to repress the androgen receptor. The authors point out that "the androgen receptor is a critical therapeutic target in prostate cancer" and that alterations in the receptor are essential for the development of castrate-resistant prostate cancer, in which the disease no longer responds to hormonal therapies.

"This research provides new insight into the mechanism of miR-125b regulation of castrate-resistance prostate cancer through the identification of a novel target for
'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Magical state of embryonic stem cells may help overcome hurdles to therapeutics
2. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
3. 2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
6. UofL research holds promise of therapeutic approach for gum disease
7. AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
8. Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy
9. Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates
10. Innate immune system protein provides a new target in war against bacterial infections
11. Antitoxin strategy may help target other pathogens
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New therapeutic target for prostate cancer identified
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... In the five months since passage of the ... of research-related awards have been made, supporting important scientific ... increase in basic research funding in American history - ... scientific research and education projects, while $3.5 billion is ...
... 30, 2009) A team of 80 researchers from ... Shifting Sands: Environmental and Cultural Change in Maryland,s Coastal ... barrier islands making up Maryland,s Atlantic coastline. Published ... the history, setting, context and ecology of these waterways, ...
... from the talents of Rembrandt, Van Gogh and other ... of colors on a palette. In a similar manner, ... (NIST) have created an innovative device called the "microfluidic ... concentration across an areain a miniature chamber about the ...
Cached Biology News:'Microfluidic palette' may paint clearer picture of biological processes 2
(Date:10/1/2014)... New applications of structures and materials that ... nature over millennia are featured in a special ... in biophotonics in the October issue of the ... by SPIE, the international society for optics and photonics, ... articles are accessible via open access. , “Biomimetic and ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... Ill. (PRWEB) October 01, 2014 The ... $9,956,011 to Southern Illinois University Edwardsville as part of ... (TAACCCT) initiative. The funding is co-administered by the Department ... Joe Biden, Secretary of Labor Thomas E. Perez and ... $450 million in job-driven training grants to nearly 270 ...
(Date:10/1/2014)... PHILADELPHIA , October 1, 2014 ... plans to software invited to engage around the theme, ... 29-30     Elsevier ... information products and services, will host a gathering of ... discuss issues and trends impacting healthcare today and in ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
... the Largest Sales Teams Promoting a 5-ASA ... 26 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: ... a co-promotion agreement with,TAP Pharmaceutical Products Inc. ... the induction of remission in patients with,active, ...
... March 26 Thomas W. Burke, MD, Executive ... M.D. Anderson,Cancer Center, has been elected the 40th ... the organization,s 39th Annual Meeting,held March 9-12, 2008 ... undergraduate and medical degrees from Tulane,University in New ...
Cached Biology Technology:Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Biology Products: